Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
January 5, 2017 --Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL-- --Momenta to host a conference call for its investors today at CSL ...